

# Report of the Guideline Development Group Meeting on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis

A review of available evidence (2016)

28 - 29 June 2016

Geneva, Switzerland



World Health  
Organization

THE  
**END TB**  
STRATEGY



**Report of the Guideline Development  
Group Meeting on the use of bedaquiline in  
the treatment of multidrug-resistant  
tuberculosis**

A review of available evidence (2016)

28 - 29 June 2016  
Geneva, Switzerland

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** Report of the Guideline Development Group Meeting on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis, A review of available evidence (2016). Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

## Table of Contents

<b>Abbreviations and acronyms</b> .....	v
<b>Acknowledgements</b> .....	vi
<b>Funding</b> .....	vi
<b>Declarations of interest</b> .....	vii
<b>Preface</b> .....	viii
<b>1. Background</b> .....	1
<b>2. Preparation for the assessment of newly available evidence</b> .....	3
<b>2.1. Evidence retrieval and synthesis</b> .....	3
<b>2.2. Further data for comparative mortality analysis</b> .....	5
<b>3. Guideline Development Group Meeting</b> .....	6
<b>3.1. Meeting objectives</b> .....	6
<b>3.2. Meeting procedures: Management of conflicts of interest</b> .....	7
<b>3.3. Assessment of evidence and its grading: The GRADE system</b> .....	7
<b>3.4. Reviewing the 2013 policy recommendation</b> .....	10
<b>4. Summary of main findings</b> .....	11
<b>4.1. Sample description and baseline characteristics</b> .....	11
<b>4.2. Effectiveness of bedaquiline in the treatment of MDR-TB</b> .....	15
<b>4.3. Safety</b> .....	19
<b>4.4. Mortality</b> .....	23
<b>5. GRADE Evidence Profile and Guideline Development Group findings</b> .....	26
<b>6. Summary of Evidence to Decision</b> .....	39
<b>6.1. Final grading of the evidence</b> .....	39
<b>6.2. Undesirable effects: balance between benefits and harms</b> .....	39
<b>6.3. Balance of desirable and undesirable effects</b> .....	40
<b>6.4. Patients' values and preferences</b> .....	40
<b>6.5. Cost-effectiveness</b> .....	40
<b>6.6. Equity</b> .....	40
<b>6.7. Acceptability</b> .....	40
<b>6.8. Feasibility</b> .....	40
<b>7. Guideline Development Group Recommendation</b> .....	41
<b>7.1. Implementation considerations</b> .....	42
<b>7.2. Monitoring and Evaluation</b> .....	42
<b>7.3. Research gaps</b> .....	43
<b>Reference list</b> .....	44
<b>Annexes</b> .....	46

---

## List of boxes, figures and tables

<b>Box 1.</b>	Summary of the main recommendations of the WHO 2013 interim policy guidance on the use of bedaquiline in the treatment of MDR-TB .....	2
<b>Fig. 1.</b>	Flow diagram for study search and selection of data .....	4
<b>Fig. 2.</b>	EDRWeb patients' records included in analysis .....	6
<b>Fig. 3.</b>	Meta-analysis of culture conversion at six months of bedaquiline treatment .....	15
<b>Fig. 4.</b>	Meta-analysis of cure rates .....	17
<b>Fig. 5.</b>	Meta-analysis of treatment completion rates .....	17
<b>Fig. 6.</b>	Meta-analysis of failure rates .....	17
<b>Fig. 7.</b>	Meta-analysis of death rates .....	18
<b>Fig. 8.</b>	Meta-analysis of lost-to-follow-up rates.....	18
<b>Fig. 9.</b>	Meta-analysis of success rates.....	18
<b>Fig. 10.</b>	Forest-plot of adjusted Hazard Ratios on a number of co-variates for Cox regressions and Logistic regression analyses .....	25
<b>Table 1.</b>	Significance of the four levels of evidence .....	9
<b>Table 2.</b>	Characteristics of included studies .....	12
<b>Table 3.</b>	Baseline characteristics of participants in the included studies.....	13
<b>Table 4.</b>	Populations used in the various analyses .....	14
<b>Table 5.</b>	Distribution of treatment outcomes .....	16
<b>Table 6.</b>	Number of patients who experienced adverse events .....	19
<b>Table 7.</b>	Distribution of all adverse events by system affected and study.....	20
<b>Table 8.</b>	Distribution of number of serious adverse events by system in all studies.....	21
<b>Table 9.</b>	Distribution of serious adverse events by system affected for all cohorts .....	21
<b>Table 10.</b>	Distribution of worst QTcF measurements .....	22
<b>Table 11.</b>	Increase in QTc from baseline to longest measurements .....	22
<b>Table 12.</b>	Average QTcF prolongation by duration on bedaquiline.....	23
<b>Table 13.</b>	Quality assessment, the GRADE evidence profile summary (2013) .....	29
<b>Table 14.</b>	Quality assessment, the GRADE evidence profile summary (2016) .....	31
<b>Table 15.</b>	The GRADE evidence to decision framework.....	33

---

## Abbreviations and acronyms

<b>aDSM</b>	active TB drug safety monitoring and management
<b>AE</b>	adverse event
<b>ART</b>	antiretroviral therapy
<b>DR-TB</b>	drug-resistant tuberculosis
<b>DST</b>	drug susceptibility testing
<b>ECG</b>	electrocardiogram
<b>GDG</b>	Guideline Development Group
<b>GRADE</b>	Grading of Recommendations Assessment, Development and Evaluation
<b>GRC</b>	WHO Guidelines Review Committee
<b>HIV</b>	human immunodeficiency virus
<b>MDR-TB</b>	multidrug-resistant tuberculosis
<b>MDR-TB<sub>+FQ</sub></b>	multidrug-resistant tuberculosis with additional resistance to fluoroquinolones
<b>MDR-TB<sub>+SLI</sub></b>	multidrug-resistant tuberculosis with additional resistance to injectable drugs
<b>MIC</b>	minimum inhibitory concentration
<b>NTP</b>	national tuberculosis control programme
<b>OBR</b>	optimised background regimen
<b>PK/PD</b>	pharmacokinetic/pharmacodynamic
<b>PMDT</b>	programmatic management of drug-resistant tuberculosis
<b>RCT</b>	randomised control trial(s)
<b>SAE</b>	serious adverse event
<b>TB</b>	tuberculosis
<b>U.S. FDA</b>	United States Food and Drug Administration
<b>WHO</b>	World Health Organization
<b>XDR-TB</b>	extensively drug-resistant tuberculosis

## Acknowledgements

This document was prepared by Christian Lienhardt and Lice González-Angulo, with the contribution of Ernesto Jaramillo, Dennis Falzon and Karin Weyer (World Health Organization (WHO) Global TB Programme), to report on the outputs of the Guideline Development Group meeting convened by WHO in Geneva on 28 - 29 June 2016, and subsequent Webinar conducted on 15 September 2016. WHO gratefully acknowledges the contributions made by the Chair of the Guideline Development Group (Holger J. Schünemann) and its members (Martien Borgdoff, Grania Brigden, Lucy Chesire, Daniela Cirillo, Gerry Davies, Poonam Dhavan, Peter Donald, Christopher Kuaban, Miranda Langendam, Mauricio Lima-Barreto, Anna Mandalakas, Beatrice Mutayoba, Payam Nahid, Viet Nhung Nguyen, Rohit Sarin, Alena Skrahina, Carlos Torres-Duque, and Carrie Tudor). WHO greatly acknowledges the work conducted by Lawrence Mbuagbaw, consultant to WHO, in the analysis and synthesis of evidence, as well as the contributions made by technical resource persons during discussions (Anneke Hesselink, Erica Lessem, Norbert Ndjeka, Kate Schnippel, and Fraser Wares).

Administrative and secretarial support: Lou Maureen Comia.

## Funding

The Bill and Melinda Gates Foundation is acknowledged for its support to the process (meeting of the GDG and systematic review) through grant project number **OPP 1126615**.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_26928](https://www.yunbaogao.cn/report/index/report?reportId=5_26928)

